Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Page 1
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Nitz U, Gluz O, Kreipe HH, Christgen M, Kuemmel S, Baehner FL, Shak S, Aktas B, Braun M, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Nuding B, Darsow M, Schumacher C, Krauss K, Malter W, Thill M, Warm M, Wuerstlein R, Kates RE, Harbeck N. Nitz U, et al. Among authors: shak s. Ther Adv Med Oncol. 2020 Nov 23;12:1758835920973130. doi: 10.1177/1758835920973130. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33281950 Free PMC article.
BACKGROUND: Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine therapy (ET), is currently not included in adjuvant treatment decisions in hormone receptor (HR)+/human epidermal growth factor receptor 2 (H …
BACKGROUND: Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine t …
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Stemmer SM, Steiner M, Rizel S, Ben-Baruch N, Uziely B, Jakubowski DM, Baron J, Shak S, Soussan-Gutman L, Bareket-Samish A, Fried G, Rosengarten O, Itay A, Nisenbaum B, Katz D, Leviov M, Tokar M, Liebermann N, Geffen DB. Stemmer SM, et al. Among authors: shak s. NPJ Breast Cancer. 2019 Nov 8;5:41. doi: 10.1038/s41523-019-0137-3. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31728408 Free PMC article.
The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer (BC). Long-term data from real-life clinical practice where treatment was guided by the RS result are l …
The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen recepto …
Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC, Miller DP, Shak S, Petkov VI. Roberts MC, et al. Among authors: shak s. Breast Cancer Res Treat. 2017 Jun;163(2):303-310. doi: 10.1007/s10549-017-4162-3. Epub 2017 Feb 27. Breast Cancer Res Treat. 2017. PMID: 28243896
Further analyses should account for treatment variables, and longitudinal updates will be important to better characterize utilization of Oncotype DX testing and long-term survival outcomes....
Further analyses should account for treatment variables, and longitudinal updates will be important to better characterize utilization of On …
Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S. Shak S. Chest. 1995 Feb;107(2 Suppl):65S-70S. doi: 10.1378/chest.107.2_supplement.65s. Chest. 1995. PMID: 7842816 Review.
In in vitro studies, rhDNase has been shown to reduce the viscoelasticity, reduce the adhesiveness, and improve the mucociliary transportability of cystic fibrosis sputum. In short-term phase 1 and phase 2 clinical trials, rhDNase has been shown to be safely tolerated and …
In in vitro studies, rhDNase has been shown to reduce the viscoelasticity, reduce the adhesiveness, and improve the mucociliary transportabi …
Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D, Geddes D, Hodson M. Ranasinha C, et al. Among authors: shak s. Lancet. 1993 Jul 24;342(8865):199-202. doi: 10.1016/0140-6736(93)92297-7. Lancet. 1993. PMID: 8100928 Clinical Trial.
There was no significant difference in side-effects between the groups. This study confirms that short-term administration of rhDNase in stable patients with cystic fibrosis is safe and improves lung function....
There was no significant difference in side-effects between the groups. This study confirms that short-term administration of rhDNase …
Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.
Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Aitken ML, et al. Among authors: shak s. JAMA. 1992 Apr 8;267(14):1947-51. JAMA. 1992. PMID: 1548827 Clinical Trial.
CONCLUSIONS: Aerosolized rhDNase appears safe in normal subjects and in adults with cystic fibrosis and may improve lung function with short-term therapy....
CONCLUSIONS: Aerosolized rhDNase appears safe in normal subjects and in adults with cystic fibrosis and may improve lung function with short …